Welcome to our dedicated page for SPRUCE BIOSCIENCES SEC filings (Ticker: SPRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Spruce Biosciences filings document the regulatory, financing and governance record of a late-stage biopharmaceutical company developing TA-ERT for Sanfilippo Syndrome Type B (MPS IIIB). Form 8-K disclosures cover material agreements, including loan and security arrangements, at-the-market equity sale agreements, collaboration and license matters, and furnished clinical data updates related to the TA-ERT program.
Proxy materials describe shareholder voting matters, director elections, board committee changes, executive compensation and equity incentive plan matters. The filing record also includes capital-structure disclosures tied to common stock, equity awards, financing arrangements, risk factors and public-company governance.
SPRUCE BIOSCIENCES, INC. filed a Form 3 identifying Corwin Dale Hooks, its Chief Commercial Officer, as a reporting person. The filing lists no transactions, indicating that no purchases, sales, acquisitions, or dispositions of SPRB securities are reported in this initial ownership statement.
Spruce Biosciences is offering up to $75.0 million of common stock under an at-the-market sales agreement with Jefferies LLC. The sales may occur from time to time on the Nasdaq Capital Market and other trading venues, with Jefferies acting as agent and receiving a 3.0% commission on gross proceeds.
The prospectus supplement states proceeds may be used to fund clinical programs and for general corporate purposes, including working capital, operating expenses and capital expenditures. The assumed illustrative offering price referenced is $55.87 per share (last reported sale price on March 6, 2026), and the filing notes potential dilution and variability in the number and timing of shares sold.
Spruce Biosciences, Inc. entered a new Open Market Sale agreement with Jefferies that allows at‑the‑market issuances of common stock under its existing shelf registration, replacing a 2022 sales agreement. The company also highlighted progress for tralesinidase alfa enzyme replacement therapy (TA‑ERT) for Sanfilippo syndrome type B following positive FDA Type B meetings and is preparing a biologics license application targeted for the fourth quarter of 2026.
For 2025, Spruce reported cash and cash equivalents of $48.9 million as of December 31, 2025, excluding $15.0 million of loan proceeds received in January 2026, and expects this cash to fund operations into early 2027. Research and development expenses fell to $19.5 million from $46.4 million in 2024, while general and administrative expenses rose to $17.0 million from $14.6 million. Total operating expenses declined to $36.5 million from $61.1 million, and net loss narrowed to $39.0 million from $53.0 million.
Spruce secured a growth capital loan facility of up to $50 million from Avenue Capital Group, including an initial fully funded $15 million tranche and three additional tranches subject to conditions. The company appointed Corwin Dale Hooks as Chief Commercial Officer with a $480,000 base salary, target bonus up to 40% of salary, and an inducement restricted stock unit grant for 11,000 shares vesting over four years to support potential commercialization of TA‑ERT.
Spruce Biosciences files its Annual Report outlining a high‑risk but focused rare‑disease strategy and a challenging financial position. The company highlights substantial doubt about its ability to continue as a going concern and says it lacks sufficient working capital for the next twelve months without new funding.
Its lead program, TA‑ERT, targets ultra‑rare MPS IIIB, where no FDA‑approved therapies exist. Long‑term studies showed normalization of key biomarkers and stabilization of cognitive function, and the FDA has agreed that CSF HS‑NRE may support accelerated approval if a confirmatory Phase 3 trial is started during biologics license review. Spruce is preparing a BLA submission, now anticipated in late 2026.
The report also details earlier‑stage assets, including tildacerfont with the Cortibon diagnostic for major depressive disorder, where a Phase 2 trial was discontinued after a serious liver enzyme elevation, and SPR202 for congenital adrenal hyperplasia, licensed from HBM with milestones up to $390.0 million. As of June 30, 2025, non‑affiliate common stock held a market value of about $2.8 million, and 1,372,043 shares were outstanding as of March 3, 2026; these figures frame the small scale of the company against its extensive development and licensing obligations.
Spruce Biosciences, Inc. reported a joint Schedule 13G showing that Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial interests in roughly 103,000 shares of common stock, representing about 9.6% of the class on the cover pages.
The filing states these holdings are held by entities subject to voting control and investment discretion by Millennium Management LLC and related managers, and includes a Joint Filing Agreement dated February 23, 2026.
Carlyle-affiliated entities and Abingworth funds report beneficial ownership of 50,893 shares of Spruce Biosciences common stock, equal to about 4.7% of the company. This percentage is based on 1,070,370 shares outstanding as of November 7, 2025, and reflects a 1-for-75 reverse stock split completed in August 2025.
The position includes 38,620 shares held by Abingworth Bioventures VII LP, 1,233 shares issuable upon stock options and 11,040 shares issuable upon standard warrants, all exercisable within 60 days. The filing notes that the reporting persons have ceased to be beneficial owners of more than five percent of Spruce’s common stock and that no transactions occurred in the past 60 days. It also records the October 2025 resignation of Bali Muralidhar from Spruce’s board of directors.
Spruce Biosciences Schedule 13G: ADAR1 Capital Management, LLC and Daniel Schneeberger report beneficial ownership of 58,000 shares of Spruce Biosciences common stock, representing 5.4% of the class. The filing attributes 50,170 shares to ADAR1 Partners, LP and 7,830 shares to Spearhead Insurance Solutions IDF, LLC as of December 31, 2025.
The percent calculation is based on 1,070,370 shares outstanding reported as of November 7, 2025 in the issuer's Form 10-Q. Mr. Schneeberger is disclosed as manager of ADAR1 Capital Management and files both for the entity and in his individual capacity.
Alyeska Investment Group and related reporting persons disclosed a 5.79% beneficial ownership stake in Spruce Biosciences, Inc. common stock as of December 31, 2025. They report beneficial ownership of 61,670 shares of common stock, with shared voting and investment power over all of these shares and no sole authority.
An exhibit states this stake includes 21,671 shares of common stock, 30,000 PIPE shares, and warrants to purchase 9,999 additional shares. The reported percentage is based on 1,065,672 Spruce Biosciences common shares outstanding, as set out in a prospectus filed on December 12, 2025. The filers certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
Citadel-affiliated funds and Kenneth Griffin report a 6.5% passive stake in Spruce Biosciences. The group may be deemed to beneficially own 70,035 shares of common stock, based on 1,070,370 shares outstanding as of November 7, 2025. Ownership is held through Citadel CEMF Investments Ltd. and Citadel Securities, with all voting and dispositive powers reported as shared, not sole. The filing is on a Schedule 13G/A basis, and the reporting persons certify the shares were not acquired to change or influence control of Spruce Biosciences.
Spruce Biosciences investor Squadron Master Fund LP and related parties report beneficial ownership of 70,000 shares of common stock, or 6.5% of the company. This percentage is based on 1,070,370 shares outstanding as of November 7, 2025, as disclosed by Spruce Biosciences.
The stake is held through private funds advised by Squadron Capital Management LLC, an exempt reporting adviser. Squadron, along with partners Matthew Sesterhenn and William Blank, share voting and dispositive power over the 70,000 shares but have no sole authority. They may be deemed beneficial owners yet expressly disclaim beneficial ownership and state the position is held in the ordinary course, without intent to change or influence control.